natgillin/translations-raw huggingface dataset:
The overall incidence and pattern of adverse reactions reported with Kinzalkomb 80 mg/25 mg was comparable with Kinzalkomb 80 mg/12.5 mg.
Celokupno pogostnost in vzorec (pojavljanja) neželenih učinkov zdravila Kinzalkomb 80 mg/25 mg so primerjali z zdravilom Kinzalkomb 80 mg/12,5 mg.
The overall incidence and pattern of adverse reactions reported with MicardisPlus 80 mg/25 mg was comparable with MicardisPlus 80 mg/12.5 mg.
Celokupno pogostnost in vzorec (pojavljanja) neželenih učinkov zdravila MicardisPlus 80 mg/25 mg so primerjali z zdravilom MicardisPlus 80 mg/12,5 mg.
The overall incidence and pattern of adverse reactions reported with telmisartan/hydrochlorothiazide 80 mg/25 mg was comparable with telmisartan/hydrochlorothiazide 80 mg/12.5 mg.
Celokupna pogostnost in vzorec (pojavljanja) neželenih učinkov sta bila pri kombinaciji telmisartana in hidroklorotiazida 80 mg/25 mg in pri kombinaciji telmisartana in hidroklorotiazida 80 mg/12,5 mg primerljiva.
The overall incidence in Tarceva-treated patients from all studies (including uncontrolled studies and studies with concurrent chemotherapy) is approximately 0.6% compared to 0.2% in patients on placebo.
Celokupna incidenca je bila pri bolnikih, ki so prejemali zdravilo Tarceva v vseh študijah (vključno z nekontroliranimi študijami in študijami s sočasno kemoterapijo) približno 0,6-% v primerjavi z 0,2-% pri bolnikih, ki so jemali placebo.
The overall incidence of adverse events in patients treated with Onglyza in this trial was similar to placebo (72.5% versus 72.2%, respectively ).
Celotna incidenca neželenih učinkov je bila pri bolnikih, ki so v tem preskušanju prejemali zdravilo Onglyza, podobna kot pri prejemnikih placeba (72,5 % v primerjavi z 72,2 %).
The overall incidence of adverse events related to depression and suicidal ideation was 8% for both Plegridy 125 micrograms every 2 weeks and placebo groups.
Celokupna incidenca neželenih učinkov, povezanih z depresijo in samomorilnimi mislimi, je bila 8 % za skupino, ki je prejemala zdravilo Plegridy 125 mikrogramov vsaka 2 tedna, in za skupino, ki je prejemala placebo.
The overall incidence of adverse reactions related to bleeding with apixaban was 10% in the apixaban vs enoxaparin studies.
Celokupna pojavnost s krvavitvami povezanih neželenih učinkov pri uporabi apiksabana je v študiji, v kateri so apiksaban primerjali z enoksaparinom, znašala 10 %.
The overall incidence of adverse reactions reported with telmisartan (41.4 %) was usually comparable to placebo (43.9 %) in placebo controlled trials.
Skupna pogostnost neželenih učinkov, o kateri so poročali za telmisartan (41,4°%), je bila večinoma primerljiva s podatki za placebo (43,9°%) v kliničnih preskušanjih nadzorovanih s placebom.
The overall incidence of adverse reactions reported with telmisartan was usually comparable to placebo (41.4 % vs 43.9 %) in controlled trials in patients treated for hypertension.
V s placebom nadzorovanih kliničnih preskušanjih pri bolnikih, ki so se zdravili zaradi hipertenzije, je bila skupna pogostnost neželenih dogodkov podobna pri telmisartanu in placebu (41,4 %v primerjavi s 43,9 %).
The overall incidence of adverse reactions reported with telmisartan was usually comparable to placebo (41.4% vs 43.9%) in placebo controlled trials in patients treated for hypertension.
V preskušanjih, kontroliranih s placebom pri bolnikih, zdravljenih zaradi hipertenzije, je bila celotna incidenca neželenih učinkov s telmisartanom po navadi primerljiva kot pri placebu (41,4 % v primerjavi s 43,9 %).
The overall incidence of any factor VIII inhibitor development (low or high) was 0.4% (1 of 233).
Skupna pojavnost nastanka katerega koli zaviralca faktorja VIII (v nizkem ali visokem titru) je bila 0,4 % (1 od 233).
The overall incidence of drug-related diarrhoea was 22 %, including 4 % with Grade 3 and 0.4 % with Grade 4.
Skupna incidenca z zdravilom povezane driske je bila 22 %, vključno s 4 % 3. stopnje in 0,4 % 4. stopnje.
The overall incidence of hallucinations and somnolence was generally higher in the escalation phase with the pramipexole group.
Pogostost halucinacij in zaspanosti je bila v fazi povečevanja odmerka na splošno večja v skupini, ki je jemala pramipeksol.
The overall incidence of hepatitis B infections was similar in patients treated with BR-CAP or with R-CHOP (0.8% vs 1.2% respectively).
Celokupna pogostnost okužbe z virusom hepatitisa B je bila podobna pri bolnikih, zdravljenih z BR-CAP ali s R-CHOP (0,8% v primerjavi z 1,2%).
The overall incidence of hepatitis B infections was similar in patients treated with BzmbR-CAP or with R-CHOP (0.8% vs 1.2% respectively).
Celokupna pogostnost okužbe z virusom hepatitisa B je bila podobna pri bolnikih, zdravljenih z BzmbR-CAP ali R-CHOP (0,8 % v primerjavi z 1,2 %).
The overall incidence of infections was 75.9% in the basiliximab group and 75.6% in the placebo group and the incidence of serious infections was 26.1% and 24.8%, respectively.
Celotna incidenca okužb je bila 75,9 % v skupini z baziliksimabom in 75,6 % v skupini s placebom; incidenca hudih okužb je bila 26,1 % v skupini s Simulectom in 24,8 % v skupini s placebom.
The overall incidence of renal and urinary adverse events was similar for Tecfidera and placebo-treated patients.
Splošna incidenca neželenih dogodkov, povezanih z ledvicami ali urinom, je bila podobna pri bolnikih, zdravljenih z zdravilom Tecfidera, in bolnikih, ki so prejemali placebo.
The overall incidence of serious adverse reactions was low and did not indicate any specific system organ involvement.
Celotna incidenca resnih neželenih učinkov je bila nizka in ni kazala na vpletenost kakšnega specifičnega organskega sistema.
The overall incidence of treatment-related adverse events among all patients in the individual studies was not significantly different between the basiliximab (7.1% - 40%) and the placebo (7.6% - 39%) treatment groups.
Celotna incidenca neželenih učinkov v zvezi z zdravljenjem se med vsemi bolniki v posameznih raziskavah ni bistveno razlikovala med skupino, zdravljeno z baziliksimabom (7,1 % - 40 %), in skupino, ki je dobivala placebo (7,6 % - 39 %).
The overall incidences of adverse reactions of bleeding, anaemia and abnormalities of transaminases (e.g., ALT levels) were numerically lower in patients on apixaban compared to enoxaparin in the phase II and phase III studies in elective hip and knee replacement surgery.
Pri bolnikih, ki so po kirurški zamenjavi kolka ali kolena v študijah II. in III. faze prejemali apiksaban, je bila celotna pojavnost neželenih učinkov, kot so krvavitev, anemije in nepravilnosti aminotransferaz (npr. vrednosti ALT) številčno manjša kot pri bolnikih, ki so prejemali enoksaparin.
The overall mean age was 59.4 years; 56.6% of patients had an ECOG performance status of 0, 43% had a value of 1 and 0.4% had a value of 2.
Celokupna povprečna starost je bila 59,4 let; splošno stanje zmogljivosti po ECOG (Eastern Cooperative Oncology Group) so pri 56,6 % bolnikov ocenili z 0, pri 43 % z 1, pri 0,4 % pa z 2.
The overall mean decrease in haemoglobin concentration for Thelin -treated patients was 0.5 g/dl (change to end of treatment).
Skupno povprečno znižanje koncentracij hemoglobina pri bolnikih, ki so prejemali zdravilo Thelin, je bilo za 0,5 g/dl (sprememba do zaključka zdravljenja).
The overall median time since most recent progression or relapse to randomization was 6 weeks.
Mediana trajanja zdravljenja od zadnjega napredovanja ali ponovitve bolezni do randomizacije je bila 6 tednov.
The overall objective response rates in the all-randomised population (investigator assessment) were 25.7% (capecitabine) vs.
Celokupen odgovor v randomiziranih skupinah (raziskovalčeva ocena) je bil 25,7 % (kapecitabin) v primerjavi s 16,7 % (shema Mayo); p < 0,0002.
The overall objective response rates in the all-randomised population (investigator assessment) were 41.6% (capecitabine + docetaxel) vs.
Celokupni objektivni odziv celotne vključene populacije je bil po oceni raziskovalca 41,6 % v skupini, ki je jemala kapecitabin in docetaksel, ter 29,7 % v skupini, ki je jemala le docetaksel (p = 0,0058).
The overall objective response rates in the all-randomised population (investigator assessment) were 41.6% (docetaxel + capecitabine) vs.
Celotna objektivna deleža odziva v vsej randomizirani populaciji (ocena raziskovalca) sta bila 41,6 % (docetaksel
The overall objective response rates in the all-randomised population (investigator assessment) were 41.6% (docetaxel + capecitabine) vs.
Celotna objektivna deleža odziva v vsej randomizirani populaciji (ocena raziskovalca) sta bila 41,6 % (docetaksel + kapecitabin) in 29,7 % (samo docetaksel), p = 0,0058.
The overall percentage of patients with antibodies to Cimzia detectable on at least one occasion up to Week 24 was 11.7% in the Phase III placebo-controlled trial in patients with psoriatic arthritis.
Pri bolnikih s psoriatičnim artritisom je bil v fazi III s placebom nadzorovanega preskušanja celotni delež bolnikov s protitelesi proti zdravilu Cimzia, ki so bila detektirana vsaj enkrat do 24. tedna, 11,7 %.
The overall percentage of treatment responders observed in study 1100.1486 (including lead-in phase), regardless of the formulation is 793/1,068 = 74.3%.
Skupni delež bolnikov, ki so se v študiji 1100.1486 (vključno z uvajalnim obdobjem) odzivali na zdravljenje je 793/1.068 = 74,3 % ne glede na farmacevtsko obliko zdravila.
The overall PFS and OS, observed in the ITT population, as determined by the core radiology laboratory assessment, are summarized in the table below:
Skupni podatki o PFS in OS pri populaciji ITT, ugotovljeni pri centralnem ocenjevanju radioloških izvidov, so povzeti v spodnji preglednici:
The overall pharmacological activity of cilostazol increases 35% when co- administered with ketoconazole.
Skupna farmakološka dejavnost cilostazola se poveča za 35 %, če se uporablja sočasno s ketokonazolom.
The overall radiation dose received by the patient over time should also be taken into account.
Upoštevati je potrebno tudi celokupno dozo sevanja, ki jo pacient prejme v določenem obdobju.
The overall response of these subjects to vardenafil became statistically significant, compared to placebo, 25 minutes after dosing.
Na splošno je odziv teh preiskovancev na vardenafil v 25 minutah po odmerjanju postal v primerjavi s placebom statistično pomemben.
The overall response rate (ORR) in the intent-to-treat (ITT) population was 48 % (CI95 % 41 % - 56 %) with a 6 % complete response (CR) and a 42 % partial response (PR) rate.
Celokupen odgovor (ORR, overall response rate) v populaciji z namenom zdraviti (ITT, the intent-to- treat) je bil 48 % (95-% interval zaupanja 41−56 %), od tega popoln odgovor (CR, complete response) pri 6 %, delni odgovor (PR, partial response) pa pri 42 %.
The overall response rate (ORR) in the intent-to-treat (ITT) population was 48 % (CI95 % 41% - 56%) with a 6% complete response (CR) and a 42% partial response (PR) rate.
Celokupen odgovor (ORR, overall response rate) v populaciji z namenom zdraviti (ITT, the intent-to- treat) je bil 48 % (95-% interval zaupanja 41−56 %), od tega popoln odgovor (CR, complete response) pri 6 %, delni odgovor (PR, partial response) pa pri 42 %.
The overall response rate (ORR) including complete response (CR) was also assessed by an IRC using the 2008 IWCLL guidelines.
IRC je po smernicah IWCLL 2008 ocenil tudi celokupni delež odziva (ORR - overall response rate), vključno s popolnim odzivom (CR - complete response).
The overall response rate point estimates for the pooled analysis of 410 patients in SABRINA stages 1 and 2 are shown in table 2.
Ocenjeni delež celokupnega odgovora za združeno analizo 410 bolnikov iz 1. in 2. stopnje preskušanja SABRINA je prikazan v preglednici 2.
The overall response rate through 24 weeks of therapy, 69% (126/183), was generally sustained through 48 weeks with 116/183 (63%) of patients with HIV-1 RNA <50c/mL (ITT-E, Snapshot algorithm).
Celotni delež odziva v 24 tednih zdravljenja, 69 % (126/183), se je na splošno ohranil do 48. tedna in 116/183 (63 %) bolnikov je imelo HIV-1 RNA < 50 kopij/ml (ITT-E, »snapshot« algoritem).
The overall response rate was 6.8% in the evaluable patients, and the median duration of response was 26.1 weeks.
Pri ocenljivih bolnikih je bil celotni delež odziva 6,8 %, povprečno trajanje odziva pa 26,1 tednov.
The overall response rate was 6.8% in the evaluable patients, and the median duration of response was weeks.
Pri ocenljivih bolnikih je bil celotni deleţ odziva 6,8 %, povprečno trajanje odziva pa 26,1 tednov.
The overall response rate was 6.8% in the evaluable patients, and the median duration of response was weeks.
Pri ocenljivih bolnikih je bil celotni delež odziva 6,8 %, mediana trajanja odziva pa 26,1 tednov.
The overall risk of side effects with Trajenta was mostly comparable to placebo and the medicine’s safety is similar to that of other dipeptidyl peptidase 4 (DPP-4) inhibitor medicines.
Skupno tveganje za pojav neželenih učinkov pri jemanju zdravila Trajenta je bilo večinoma primerljivo s tveganjem pri placebu, varnost zdravila pa je podobna varnosti drugih zdravil, ki vsebujejo zaviralce dipeptidil peptidaze (DPP-4).
The overall safety profile in HCV-infected transplant recipients who were administered Exviera and ombitasvir/paritaprevir/ritonavir and ribavirin (in addition to their immunosuppressant medicinal products) was similar to subjects treated with Exviera and ombitasvir/paritaprevir/ritonavir and ribavirin in phase 3 clinical trials, although some adverse reactions were increased in frequency.
Celotne varnostne značilnosti pri prejemnikih presadka, okuženih s HCV, ki so prejemali zdravilo Exviera in kombinacijo ombitasvir/paritaprevir/ritonavir ter ribavirin (poleg imunosupresivnih zdravil), je bila podobna kot pri preiskovancih, zdravljenih z zdravilom Exviera in kombinacijo ombitasvir/paritaprevir/ritonavir ter ribavirinom v kliničnih preskušanjih 3. faze, čeprav so bili nekateri neželeni učinki pogostejši.
The overall safety profile in HCV-infected transplant recipients who were administered Viekirax and dasabuvir and ribavirin (in addition to their immunosuppressant medications) was similar to subjects treated with Viekirax and dasabuvir and ribavirin in phase 3 clinical trials, although some adverse reactions were increased in frequency.
Celotne varnostne značilnosti pri prejemnikih presadka, okuženih s HCV, ki so (poleg imunosupresivnih zdravil) prejemali zdravilo Viekirax in dasabuvir ter ribavirin, je bila podobna kot pri preiskovancih, zdravljenih z zdravilom Viekirax in dasabuvirjem ter ribavirinom v kliničnih preskušanjih 3. faze, a nekateri neželeni učinki so bili pogostejši.
The overall safety profile in HCV/HIV-1 co-infected subjects was similar to that observed in HCV mono- infected subjects.
Celotne varnostne značilnosti pri preiskovancih sočasno okuženih s HCV in HIV-1 so bile podobne, kot so jih opažali pri preiskovancih, okuženih samo s HCV.
The overall safety profile in HCV/HIV-1 co-infected subjects was similar to that observed in HCV mono-infected subjects.
Celotne varnostne značilnosti pri preiskovancih sočasno okuženih s HCV in HIV-1 so bile podobne kot so jih opažali pri preiskovancih, okuženih samo s HCV.
The overall safety profile of Avastin is based on data from over 5,400 patients with various malignancies, predominantly treated with Avastin in combination with chemotherapy in clinical trials.
Celotni varnostni profil zdravila Avastin temelji na podatkih več kot 5400 bolnikov z različnimi malignimi boleznimi, ki so se v kliničnih preskušanjih večinoma zdravili z zdravilom Avastin v kombinaciji s kemoterapijo.
The overall safety profile of INCIVO is based on Phase 2 and 3 clinical trial data (both controlled and uncontrolled) containing 3,441 patients who received INCIVO combination treatment and on spontaneous postmarketing reports.
Celokupni varnostni profil zdravila INCIVO temelji na podatkih iz kliničnih preskušanj faze II in III (nadzorovanih in nenadzorovanih), v katera je bilo vključenih 3.441 bolnikov, ki so prejemali kombinirano zdravljenje z zdravilom INCIVO in na spontanih poročilih iz obdobja trženja zdravila.
The overall safety profile of MabThera in non-Hodgkin’s lymphoma and CLL is based on data from patients from clinical trials and from post-marketing surveillance.
Celotni varnostni profil zdravila MabThera pri ne-Hodgkinovem limfomu in kronični limfocitni levkemiji (KLL) temelji na podatkih bolnikov iz kliničnih preskušanj in iz nadzora med obdobjem trženja.
The overall safety profile of Neuraceq is based on data from 1090 administrations of Neuraceq to 872 subjects and 12 subjects who received vehicle.
Celotni varnostni profil zdravila Neuraceq temelji na podatkih, ki se nanašajo na 1090 aplikacij zdravila Neuraceq 872 preiskovancem in na 12 preiskovancev, ki so prejeli pomožno snov.
The overall safety profile of ofatumumab in CLL (previously untreated and relapsed or refractory) is based on data from 511 patients in clinical trials (see section 5.1).
Ocena celotnega varnostnega profila ofatumumaba pri KLL (predhodno nezdravljeni bolniki in bolniki z recidivom ali refraktarno boleznijo) temelji na podatkih o 511 bolnikih v kliničnih študijah (glejte poglavje 5.1).
The overall safety profile of Prolia was similar in patients with osteoporosis and in breast or prostate cancer patients receiving hormone ablation in five Phase III placebo-controlled clinical trials.
V celoti so bile varnostne značilnosti zdravila Prolia podobne pri bolnikih z osteoporozo ter bolnicah z rakom dojke ali bolnikih z rakom prostate, deležnih ablacije hormonov, v petih s placebom kontroliranih kliničnih preskušanjih III. faze.
The overall safety profile of Revlimid in patients with mantle cell lymphoma is based on data from 254 patients from a Phase II randomized, controlled study MCL-002 (see section 5.1).
Celotni varnostni profil zdravila Revlimid pri bolnikih z limfomom plaščnih celic temelji na podatkih, pridobljenih od 254 bolnikov v študiji MCL-002, ki je bila randomizirana, kontrolirana študija faze II (glejte poglavje 5.1).
The overall safety profile of Revlimid in patients with myelodysplastic syndromes is based on data from a total of 286 patients from one Phase II study and one Phase III study (see section 5.1).
Celotni varnostni profil zdravila Revlimid pri bolnikih z mielodisplastičnimi sindromi temelji na podatkih skupno 286 bolnikov iz ene študije faze II in ene študije faze III (glejte poglavje 5.1).
The overall safety profile of Stivarga is based on data from more than 1,200 treated patients in clinical trials including placebo-controlled phase III data for 500 patients with metastatic colorectal cancer (CRC) and 132 patients with gastrointestinal stromal tumours (GIST).
Splošni varnostni profil zdravila Stivarga temelji na podatkih pri več kot 1.200 zdravljenih bolnikih v kliničnih preskušanjih, vključno s podatki iz s placebom nadzorovane III. faze pri 500 bolnikih z metastatskim kolorektalnim rakom in 132 bolnikih z gastrointestinalnimi stromalnimi tumorji (GIST).
The overall safety profile of Tamiflu is based on data from 6049 adult/adolescent and 1473 paediatric patients treated with Tamiflu or placebo for influenza, and on data from 3990 adult/adolescent and 253 paediatric patients receiving Tamiflu or placebo/no treatment for the prophylaxis of influenza in clinical trials.
Splošni varnostni profil zdravila Tamiflu je osnovan na podatkih 6049 odraslih/mladostnikov in 1473 pediatričnih bolnikov, ki so se zdravili za gripo z zdravilom Tamiflu ali placebom, in na podatkih 3990 odraslih/mladostnikov in 253 pediatričnih bolnikov, ki so v kliničnih študijah za profilakso gripe prejemali zdravilo Tamiflu ali placebo/niso prejemali zdravljenja.
The overall safety profile of VIZAMYL is based on data from its administrations to 831 subjects.
Celovit varnostni profil zdravila VIZAMYL temelji na podatkih 831 oseb, ki so prejele zdravilo.
The overall safety profile of Xadago is based on the clinical development program performed in over 3000 subjects, of whom over 500 were treated for more than 2 years
Skupni varnostni profil zdravila Xadago temelji na programu kliničnega razvoja, ki so ga opravili z več kot 3000 preskušanci, od katerih je bilo prek 500 preskušancev zdravljenih več kot 2 leti.
The overall safety profile of Zevalin after pretreatment with rituximab is based on data from 349 patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma studied in five clinical trials, on data from a study with 204 patients receiving Zevalin as consolidation therapy after first-line remission induction, and from post-marketing surveillance.
Splošni varnostni profil zdravila Zevalin po predhodnem zdravljenju z rituksimabom temelji na podatkih, zbranih na 349 bolnikih z relapsnim ali nedozivnim nizkostopenjskim, folikularnim ne– Hodgkinovim limfomom ali z NHL s transformacijo celic B, preučenih v petih kliničnih preskušanjih, iz podatkov študije z 204 bolniki, ki so prejemali zdravilo Zevalin kot konsolidacijsko zdravljenje po nastopu remisije z zdravljenjem prvega izbora in iz spremljanja po obdobju trženja.
The overall safety profile was considered acceptable and comparable to other phosphate binders.
Splošni varnostni profil je bil sprejemljiv in primerljiv z drugimi snovmi, ki vežejo fosfate.
The overall safety profile with respect to adverse events was similar between the two groups over the 24-month period.
V 24-mesečnem obdobju je bil celokupen varnostni profil glede na neželene učinke podoben med obema skupinama.
The overall selection frequency for M184V or M184I was high (54%), and less common was the selection of L74V (5%), K65R (1%) and Y115F (1%) (see table below).
Celotna pogostnost selekcije M184V ali M184I je bila visoka (54 %), redkejše so bile selekcije L74V (5 %), K65R (1 %) in Y115F (1 %) (glejte spodnjo tabelo).
The overall success rate (complete or partial response) after 15 cycles of treatment was 57 % (CI: 44 - 70 %) in liposomal anthracycline-resistant patients.
Skupna stopnja uspešnosti (popoln ali delni odziv) po 15 krogih zdravljenja pri bolnikih, odpornih proti liposomskim antraciklinom, je bila 57-odstotna (CI 44 – 70 %).
The overall survival is 65 months since diagnosis (range 25-234).
Celotno preživetje je 65 mesecev od postavitve ern a (od 25 do 234 mesecev).
The overfill ensures that after dilution with the entire extractable volume of the accompanying solvent vial for Docefrez, there is a minimal extractable reconstituted solution of 3.36 ml containing 80 mg docetaxel (anhydrous).
Prenapolnjenje zagotavlja, da je po razredčitvi s celotnim izločljivim volumnom raztopine viale za Docefrez, minimalni izločljivi volumen 3,36 ml, ki vsebuje 80 mg docetaksela (brez vode).
The overfills are included to ensure that, after dilution with the entire volume of the accompanying solvent vial, the minimum extractable volume of reconstituted concentrate containing 20 mg or 80 mg docetaxel, respectively, may be withdrawn from the vial.
Vključena prekomerna količina zagotavlja da je, po razredčitvi celotne količine priložene viale vehikla, najmanjša izločljiva količina pripravljenega koncentrata, ki individualno vsebuje 20 mg ali 80 mg docetaksela, lahko odstranjena iz viale.
The ovulation suppression
Zaviranja ovulacije s
The OZURDEX matrix slowly degrades to lactic acid and glycolic acid through simple hydrolysis, then further degrades into carbon dioxide and water.
Matriks zdravila OZURDEX se z navadno hidrolizo počasi razgradi na mlečno in glikolno kislino, potem pa naprej na ogljikov dioksid in vodo.
The PAC should include the following information for the healthcare professional information regarding Ranexa:
Kartica KOB mora vsebovati naslednje informacije za zdravnike o zdravilu Ranexa:
The PAC should include the following information for the patient:
Kartica KOB mora vsebovati naslednje informacije za bolnika:
The pack also contains 5 x 5 ml syringes with 0.1 ml graduations from 0 to 5 ml (400/100 mg).
Pakiranje vsebuje tudi pet 5- ml brizg z 0,1-ml oznakami od 0 do 5 ml (400/100 mg).
The pack also contains a 30 ml polypropylene measuring cup with 1.0 ml graduations.
Pakiranje vsebuje še 30 ml polipropilensko merico z 1,0 ml skalo.